HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gregory B Lesinski Selected Research

FLLL 32

1/2012Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
8/2010A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
6/2010The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gregory B Lesinski Research Topics

Disease

52Neoplasms (Cancer)
11/2022 - 01/2004
29Melanoma (Melanoma, Malignant)
01/2017 - 01/2004
16Pancreatic Neoplasms (Pancreatic Cancer)
01/2022 - 07/2013
10Adenocarcinoma
11/2022 - 02/2015
8Colorectal Neoplasms (Colorectal Cancer)
11/2021 - 08/2010
6Biliary Tract Neoplasms (Biliary Tract Cancer)
10/2022 - 02/2016
5Carcinogenesis
01/2019 - 03/2012
5Inflammation (Inflammations)
11/2017 - 03/2012
4Neoplasm Metastasis (Metastasis)
01/2020 - 09/2005
4Cachexia
01/2019 - 12/2015
4Chronic Pancreatitis
11/2018 - 01/2016
4Renal Cell Carcinoma (Grawitz Tumor)
04/2014 - 03/2005
3Disease Progression
11/2019 - 01/2018
2Pancreatic Diseases (Pancreatic Disease)
01/2021 - 01/2016
2Hypoxia (Hypoxemia)
01/2019 - 10/2013
2Fibrosis (Cirrhosis)
11/2017 - 04/2017
2Prostatic Neoplasms (Prostate Cancer)
11/2015 - 11/2015
2Colitis
01/2015 - 06/2014
2Dysbiosis
01/2015 - 06/2014
2Multiple Myeloma
12/2014 - 08/2010
1Infections
01/2022
1Virus Diseases (Viral Diseases)
01/2022
1Cholangiocarcinoma
01/2022
1Gallbladder Neoplasms (Gallbladder Cancer)
01/2022
1Vesicular Stomatitis
01/2022
1Exanthema (Rash)
12/2021
1Thrombocytopenia (Thrombopenia)
12/2021
1Neutropenia
11/2021
1HIV Infections (HIV Infection)
01/2020
1Microsatellite Instability
01/2020
1Rectal Neoplasms (Rectal Cancer)
01/2020
1Squamous Cell Carcinoma of Head and Neck
09/2019

Drug/Important Bio-Agent (IBA)

17CytokinesIBA
10/2022 - 09/2009
10Biomarkers (Surrogate Marker)IBA
01/2022 - 02/2015
10Proteins (Proteins, Gene)FDA Link
01/2022 - 04/2010
9Interferon-alpha (Interferon Alfa)IBA
11/2016 - 01/2004
8Interleukin-6 (Interleukin 6)IBA
01/2020 - 09/2011
8InterferonsIBA
01/2018 - 03/2005
6Immune Checkpoint InhibitorsIBA
01/2022 - 06/2015
5Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
10/2022 - 02/2016
5Bortezomib (Velcade)FDA Link
01/2016 - 10/2008
5STAT1 Transcription FactorIBA
02/2010 - 01/2004
4Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
01/2022 - 11/2016
4CurcuminIBA
01/2012 - 09/2009
3Heat-Shock Proteins (Heat-Shock Protein)IBA
01/2019 - 01/2017
3MicroRNAs (MicroRNA)IBA
01/2016 - 10/2013
3Interleukin-2 (IL2)IBA
04/2014 - 08/2008
3Annexin A5IBA
01/2014 - 06/2010
3FLLL 32IBA
01/2012 - 06/2010
3Interleukin-12 (IL 12)IBA
09/2008 - 06/2004
3Interferon alpha-2 (Roferon-A)FDA Link
08/2007 - 09/2004
2Interleukin-10 (Interleukin 10)IBA
01/2022 - 09/2011
2B7-H1 AntigenIBA
12/2021 - 01/2019
2cobimetinibIBA
12/2021 - 10/2021
2atezolizumabIBA
12/2021 - 10/2021
2Biological ProductsIBA
11/2018 - 09/2010
2AntibodiesIBA
01/2018 - 01/2017
2AntigensIBA
01/2018 - 02/2015
2Proteasome Endopeptidase Complex (Proteasome)IBA
12/2017 - 12/2009
2Proteasome InhibitorsIBA
12/2017 - 12/2009
2STA 9090IBA
12/2017 - 01/2017
2CeruletideIBA
11/2017 - 04/2017
2Lipase (Acid Lipase)FDA Link
04/2017 - 12/2015
2ChemokinesIBA
01/2017 - 01/2016
2selinexorIBA
01/2017 - 01/2014
2Paclitaxel (Taxol)FDA LinkGeneric
06/2016 - 05/2010
2DNA (Deoxyribonucleic Acid)IBA
02/2016 - 08/2010
2Messenger RNA (mRNA)IBA
01/2016 - 12/2015
2IsoflavonesIBA
11/2015 - 11/2015
2PhytochemicalsIBA
11/2015 - 09/2014
2Sorafenib (BAY 43-9006)FDA Link
09/2015 - 04/2014
2mangostinIBA
01/2015 - 06/2014
2xanthoneIBA
01/2015 - 06/2014
2Caspase 3 (Caspase-3)IBA
12/2014 - 08/2010
2Propidium (Propidium Iodide)IBA
01/2014 - 06/2010
2STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
07/2013 - 08/2010
2Small Interfering RNA (siRNA)IBA
01/2013 - 04/2010
2Suppressor of Cytokine Signaling ProteinsIBA
04/2010 - 04/2007
2InterleukinsIBA
09/2009 - 10/2006
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2008 - 08/2007
2Janus KinasesIBA
12/2005 - 06/2004
1Neoplasm Antigens (Tumor Antigens)IBA
01/2022
1ArginaseIBA
01/2022
1LigandsIBA
12/2021
1pembrolizumabIBA
11/2021
1bioplexIBA
11/2021
1IpilimumabIBA
08/2021
1NivolumabIBA
08/2021
1pepinemabIBA
08/2021
1quinone (benzoquinone)IBA
01/2020
1napabucasinIBA
01/2020
1NAD (NADH)IBA
01/2020
1Oxidoreductases (Dehydrogenase)IBA
01/2020

Therapy/Procedure

29Therapeutics
11/2022 - 09/2005
15Immunotherapy
10/2022 - 06/2004
7Drug Therapy (Chemotherapy)
10/2022 - 03/2005
3Radiotherapy
01/2020 - 03/2005
1Immunomodulation
10/2021
1Chemoradiotherapy
01/2020
1Neoadjuvant Therapy
01/2020